Clinical Trial Update: Safety and Efficacy of GPRC5D CAR-T Cell Therapy in Relapsed/Refractory Plasma Cell Disorders [EARLY_Phase 1]

View source ↗

Summary

An early-phase Phase 1 trial evaluating a GPRC5D-targeted CAR-T cell therapy for relapsed/refractory plasma cell disorders, with the study not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Al Amyloidosis
• Multiple Myeloma

Drugs mentioned

• GPRC5D CAR-T cell therapy (GPRC5D-targeted CAR-T cell therapy)

Snippet

Sponsor: Qi deng | Conditions: Plasma Cell Dyscrasias | EARLY_Phase 1 | Status: NOT_YET_RECRUITING